Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CBM's Cash to Debt is ranked higher than
99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. CBM: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CBM' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.25 Max: No Debt
Current: No Debt
Equity to Asset 0.66
CBM's Equity to Asset is ranked lower than
52% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBM: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
CBM' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.44 Max: 0.74
Current: 0.66
0.22
0.74
Interest Coverage 1842.71
CBM's Interest Coverage is ranked lower than
65% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBM: 1842.71 )
Ranked among companies with meaningful Interest Coverage only.
CBM' s Interest Coverage Range Over the Past 10 Years
Min: 1.97  Med: 10.04 Max: No Debt
Current: 1842.71
F-Score: 7
Z-Score: 7.31
M-Score: -2.48
WACC vs ROIC
18.64%
23.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.91
CBM's Operating margin (%) is ranked higher than
88% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. CBM: 21.91 )
Ranked among companies with meaningful Operating margin (%) only.
CBM' s Operating margin (%) Range Over the Past 10 Years
Min: -2.77  Med: 10.34 Max: 21.91
Current: 21.91
-2.77
21.91
Net-margin (%) 13.97
CBM's Net-margin (%) is ranked higher than
84% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. CBM: 13.97 )
Ranked among companies with meaningful Net-margin (%) only.
CBM' s Net-margin (%) Range Over the Past 10 Years
Min: -98.33  Med: 6.29 Max: 82.87
Current: 13.97
-98.33
82.87
ROE (%) 20.75
CBM's ROE (%) is ranked higher than
93% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CBM: 20.75 )
Ranked among companies with meaningful ROE (%) only.
CBM' s ROE (%) Range Over the Past 10 Years
Min: -94.37  Med: 12.78 Max: 120.02
Current: 20.75
-94.37
120.02
ROA (%) 12.39
CBM's ROA (%) is ranked higher than
92% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. CBM: 12.39 )
Ranked among companies with meaningful ROA (%) only.
CBM' s ROA (%) Range Over the Past 10 Years
Min: -37.93  Med: 4.65 Max: 42.71
Current: 12.39
-37.93
42.71
ROC (Joel Greenblatt) (%) 35.01
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. CBM: 35.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CBM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1.19  Med: 12.69 Max: 35.01
Current: 35.01
-1.19
35.01
Revenue Growth (3Y)(%) 13.40
CBM's Revenue Growth (3Y)(%) is ranked higher than
67% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CBM: 13.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CBM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.1  Med: 0.3 Max: 13.4
Current: 13.4
-18.1
13.4
EBITDA Growth (3Y)(%) 22.30
CBM's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. CBM: 22.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CBM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.2  Med: -0.5 Max: 33.1
Current: 22.3
-27.2
33.1
EPS Growth (3Y)(%) -5.60
CBM's EPS Growth (3Y)(%) is ranked lower than
51% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CBM: -5.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CBM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.5  Med: 7.8 Max: 79.7
Current: -5.6
-21.5
79.7
» CBM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CBM Guru Trades in Q3 2015

Jim Simons 348,100 sh (-1.97%)
Paul Tudor Jones 20,971 sh (-6.76%)
Chuck Royce 337,500 sh (-20.49%)
Joel Greenblatt 137,090 sh (-48.98%)
» More
Q4 2015

CBM Guru Trades in Q4 2015

Jim Simons 319,200 sh (-8.30%)
Joel Greenblatt 110,565 sh (-19.35%)
Chuck Royce 201,500 sh (-40.30%)
Paul Tudor Jones 6,000 sh (-71.39%)
» More
Q1 2016

CBM Guru Trades in Q1 2016

Columbia Wanger 287,570 sh (New)
Third Avenue Management 76,681 sh (New)
Paul Tudor Jones 7,400 sh (+23.33%)
Chuck Royce 203,298 sh (+0.89%)
Joel Greenblatt Sold Out
Jim Simons 162,300 sh (-49.15%)
» More
Q2 2016

CBM Guru Trades in Q2 2016

Steven Cohen 111,900 sh (New)
RS Investment Management 84,110 sh (New)
Columbia Wanger 314,909 sh (+9.51%)
Third Avenue Management 76,681 sh (unchged)
Paul Tudor Jones 7,164 sh (-3.19%)
Chuck Royce 170,598 sh (-16.08%)
Jim Simons 34,300 sh (-78.87%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RLYP, NAS:INVA, OTCPK:SXMDF, NAS:TBPH, NAS:AGIO, NAS:ALDR, NAS:CHRS, NYSE:AXON, OTCPK:PFSCF, NAS:HALO, NAS:FPRX, NAS:AAAP, NAS:LXRX, NAS:SRPT, NYSE:PBYI, NAS:ACHN, NAS:CEMP, NAS:SAGE, NAS:DBVT, NAS:FGEN » details
Traded in other countries:XBX.Germany,
Cambrex Corp is a life sciences company. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.

Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company supplies its products and services to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Its customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The products and services are supplied globally to innovator and generic drug companies. Its products include APIs, pharmaceutical intermediates and other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The Company owns 22 issued patents and has 3 patent applications pending in the United States and owns over 190 patents and has over 100 patent applications pending in foreign countries covering various technologies. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.

Ratios

vs
industry
vs
history
P/E(ttm) 22.94
CBM's P/E(ttm) is ranked higher than
60% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 28.72 vs. CBM: 22.94 )
Ranked among companies with meaningful P/E(ttm) only.
CBM' s P/E(ttm) Range Over the Past 10 Years
Min: 1.05  Med: 15.5 Max: 59.25
Current: 22.94
1.05
59.25
Forward P/E 17.73
CBM's Forward P/E is ranked higher than
62% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. CBM: 17.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.71
CBM's PE(NRI) is ranked higher than
61% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 22.71 )
Ranked among companies with meaningful PE(NRI) only.
CBM' s PE(NRI) Range Over the Past 10 Years
Min: 5.27  Med: 16.35 Max: 94.8
Current: 22.71
5.27
94.8
Price/Owner Earnings (ttm) 28.62
CBM's Price/Owner Earnings (ttm) is ranked higher than
53% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 33.65 vs. CBM: 28.62 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CBM' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.28  Med: 18.74 Max: 364.38
Current: 28.62
1.28
364.38
P/B 4.10
CBM's P/B is ranked lower than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CBM: 4.10 )
Ranked among companies with meaningful P/B only.
CBM' s P/B Range Over the Past 10 Years
Min: 0.61  Med: 2.19 Max: 5.9
Current: 4.1
0.61
5.9
P/S 3.19
CBM's P/S is ranked higher than
80% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. CBM: 3.19 )
Ranked among companies with meaningful P/S only.
CBM' s P/S Range Over the Past 10 Years
Min: 0.18  Med: 1.3 Max: 10.86
Current: 3.19
0.18
10.86
PFCF 32.99
CBM's PFCF is ranked lower than
58% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. CBM: 32.99 )
Ranked among companies with meaningful PFCF only.
CBM' s PFCF Range Over the Past 10 Years
Min: 4.86  Med: 15.89 Max: 276
Current: 32.99
4.86
276
POCF 13.56
CBM's POCF is ranked higher than
72% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 22.41 vs. CBM: 13.56 )
Ranked among companies with meaningful POCF only.
CBM' s POCF Range Over the Past 10 Years
Min: 2.91  Med: 10.86 Max: 63.52
Current: 13.56
2.91
63.52
EV-to-EBIT 13.73
CBM's EV-to-EBIT is ranked higher than
67% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. CBM: 13.73 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s EV-to-EBIT Range Over the Past 10 Years
Min: -118.8  Med: 11.9 Max: 306.6
Current: 13.73
-118.8
306.6
EV-to-EBITDA 11.21
CBM's EV-to-EBITDA is ranked higher than
70% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. CBM: 11.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.8  Med: 8 Max: 35.9
Current: 11.21
-0.8
35.9
PEG 1.22
CBM's PEG is ranked higher than
71% of the 93 Companies
in the Global Biotechnology industry.

( Industry Median: 2.24 vs. CBM: 1.22 )
Ranked among companies with meaningful PEG only.
CBM' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.28 Max: 7.94
Current: 1.22
0.48
7.94
Shiller P/E 27.17
CBM's Shiller P/E is ranked higher than
73% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.61 vs. CBM: 27.17 )
Ranked among companies with meaningful Shiller P/E only.
CBM' s Shiller P/E Range Over the Past 10 Years
Min: 2.83  Med: 30.73 Max: 435.33
Current: 27.17
2.83
435.33
Current Ratio 3.47
CBM's Current Ratio is ranked lower than
58% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. CBM: 3.47 )
Ranked among companies with meaningful Current Ratio only.
CBM' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.57 Max: 5.19
Current: 3.47
0.9
5.19
Quick Ratio 1.73
CBM's Quick Ratio is ranked lower than
75% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CBM: 1.73 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.43 Max: 4.55
Current: 1.73
0.5
4.55
Days Inventory 170.93
CBM's Days Inventory is ranked lower than
62% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. CBM: 170.93 )
Ranked among companies with meaningful Days Inventory only.
CBM' s Days Inventory Range Over the Past 10 Years
Min: 124.14  Med: 131.78 Max: 170.93
Current: 170.93
124.14
170.93
Days Sales Outstanding 53.42
CBM's Days Sales Outstanding is ranked higher than
57% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. CBM: 53.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.84  Med: 61.31 Max: 81.77
Current: 53.42
49.84
81.77
Days Payable 48.96
CBM's Days Payable is ranked lower than
53% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. CBM: 48.96 )
Ranked among companies with meaningful Days Payable only.
CBM' s Days Payable Range Over the Past 10 Years
Min: 37.86  Med: 51.72 Max: 69.01
Current: 48.96
37.86
69.01

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
CBM's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CBM: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.1  Med: -1.6 Max: -0.1
Current: -2.1
-4.1
-0.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 14.76
CBM's Price/Net Current Asset Value is ranked lower than
78% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. CBM: 14.76 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CBM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.47  Med: 21.04 Max: 107.17
Current: 14.76
2.47
107.17
Price/Tangible Book 4.53
CBM's Price/Tangible Book is ranked lower than
52% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. CBM: 4.53 )
Ranked among companies with meaningful Price/Tangible Book only.
CBM' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 3.96 Max: 14.12
Current: 4.53
1.62
14.12
Price/Projected FCF 2.35
CBM's Price/Projected FCF is ranked higher than
63% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. CBM: 2.35 )
Ranked among companies with meaningful Price/Projected FCF only.
CBM' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.83  Med: 2.23 Max: 12.66
Current: 2.35
0.83
12.66
Price/Median PS Value 2.40
CBM's Price/Median PS Value is ranked lower than
85% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CBM: 2.40 )
Ranked among companies with meaningful Price/Median PS Value only.
CBM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.18 Max: 7.24
Current: 2.4
0.21
7.24
Price/Peter Lynch Fair Value 1.19
CBM's Price/Peter Lynch Fair Value is ranked higher than
62% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 1.64 vs. CBM: 1.19 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBM' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.57  Med: 1.24 Max: 8.25
Current: 1.19
0.57
8.25
Price/Graham Number 2.12
CBM's Price/Graham Number is ranked higher than
65% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. CBM: 2.12 )
Ranked among companies with meaningful Price/Graham Number only.
CBM' s Price/Graham Number Range Over the Past 10 Years
Min: 0.8  Med: 1.79 Max: 4.29
Current: 2.12
0.8
4.29
Earnings Yield (Greenblatt) (%) 7.24
CBM's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CBM: 7.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 8 Max: 209.9
Current: 7.24
0.3
209.9
Forward Rate of Return (Yacktman) (%) 20.49
CBM's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.44 vs. CBM: 20.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBM' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -35.3  Med: 1 Max: 20.7
Current: 20.49
-35.3
20.7

More Statistics

Revenue (TTM) (Mil) $462.5
EPS (TTM) $ 1.96
Beta2.36
Short Percentage of Float7.45%
52-Week Range $29.50 - 59.41
Shares Outstanding (Mil)32.15

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17
Revenue (Mil $)
EPS ($) 2.49 3.04
EPS w/o NRI ($) 2.49 3.04
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:CBM

Headlines

Articles On GuruFocus.com
Third Avenue Comments on Cambrex Corp May 27 2016 
Chip Rewey's Third Avenue Small-Cap Value Fund 2nd Quarter Commentary May 27 2016 
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
ETF’s with exposure to Cambrex Corp. : August 22, 2016 Aug 22 2016
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline Aug 10 2016
Is Cambrex Corporation (CBM) a Great Growth Stock? Aug 04 2016
Cambrex Corp. :CBM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016 Aug 03 2016
CAMBREX CORP Financials Aug 03 2016
Cambrex posts 2Q profit Jul 28 2016
Cambrex posts 2Q profit Jul 28 2016
Cambrex Corp Earnings Call scheduled for 8:30 am ET today Jul 28 2016
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 28 2016
Cambrex Reports Second Quarter 2016 Financial Results Jul 28 2016
CAMBREX CORP Files SEC form 10-Q, Quarterly Report Jul 28 2016
Q2 2016 Cambrex Corp Earnings Release - Before Market Open Jul 28 2016
Cambrex Reports Second Quarter 2016 Financial Results Jul 28 2016
Cambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : July 27, 2016 Jul 27 2016
Stocks Try To Close Higher, But Bears Swat Centene, Mobileye Jul 26 2016
Cambrex to Announce Second Quarter 2016 Financial Results on July 28, 2016 Jul 26 2016
Cambrex to Announce Second Quarter 2016 Financial Results on July 28, 2016 Jul 26 2016
Cambrex Completes $50 Million Investment in Large Scale API Manufacturing and Storage at Its Charles... Jul 12 2016
Cambrex Completes $50 Million Investment in Large Scale API Manufacturing and Storage at Its Charles... Jul 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)